Shaun O’Neil Named COO at PAVmed

PAVmed Inc. has promoted Chief Commerical Officer Shaun O’Neil to executive vice president and chief operating officer (COO), putting him in charge of operations and commercial activities throughout the company and its subsidiaries. He will serve on the company’s Executive Committee and as an executive officer.
 
“Mr. O’Neil has been an invaluable member of our company and its leadership team since joining us nearly four years ago, including playing a central role in our transition to a commercial enterprise,” said Lishan Aklog M.D., PAVmed’s chairman and CEO. “He has built a solid and rapidly expanding commercial infrastructure—including sales, marketing, and market access—most notably for Lucid and its products, as well as nascent commercial teams for other commercial and near-commercial products. He has also played important roles in numerous other critical corporate initiatives, including the launch of our Lucid Test Center network, our transition to a dedicated CLIA-certified laboratory and in various business development activities. His deep involvement in operational and commercial activities across the breadth of the company make him the ideal candidate to serve as our inaugural COO, a position launched to accommodate our rapid growth to nearly one hundred employees over the past year.”
 
O’Neil has served as PAVmed’s chief commercial officer and executive vice president, Business Development, since 2018. Prior to PAVmed, O’Neil brought to PAVmed more than 15 years of sales and marketing leadership, and product and business development expertise in both startup and established companies, including a particularly strong track record in growing sales and increasing market share for medical devices. From 2011 to 2018 O’Neil held various sales and marketing leadership positions with AngioDynamics, a provider of medical devices used by interventional radiologists, interventional cardiologists, surgeons, and other physicians for the minimally invasive diagnosis and treatment of cancer and peripheral vascular disease. Prior to AngioDynamics, he served in various sales, marketing and engineering roles at Aycan Medical Systems, a privately held medical imaging company, Harris Interactive and Quality Solutions Group.

O’Neil earned a bachelor’s degree in business administration from Alfred University and an MBA from the Rochester Institute of Technology.

“I am energized to take on this expanded role at such an exciting time for PAVmed and its subsidiaries,” said O’Neil. “We are in as strong a position as ever to execute on our strategic plan, drive commercialization of our products and grow long-term shareholder value. That strength is built on a solid balance sheet, groundbreaking technologies, and the best team in the industry. I look forward helping execute on our vision to transform PAVmed into a leading global medical technology company.”
 
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc., markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure Esophageal Ablation Device with Caldus Technology, which complements EsoGuard and EsoCheck, the NextFlo Intravenous Infusion Set, the PortIO Implantable Intraosseous Vascular Access Device, pediatric ear tubes, mechanical circulatory support technology and glucose monitoring.